

DOCKET NO.: TRTC-0003

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Ramesh Babu Jayaraman, et al.

Application No.: 10/813, 315

Filing Date: March 30, 2004

Confirmation No.: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

For: AGENT ELUTING BIOMPLANTABLE DEVICES AND POLYMER
SYSTEMS FOR THEIR PREPARATION

DATE OF DEPOSIT: May 6, 2004

I HEREBY CERTIFY THAT THIS PAPER IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID,
ON THE DATE INDICATED ABOVE AND IS
ADDRESSED TO THE UNITED STATES PATENT AND
TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA,
VA 22313-1450.

TYPED NAME: Elizabeth A. McLoud

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

☐ In accordance with § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached;

or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

- ☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith
- ☒ Copies of references listed on the attached Form PTO 1449 are not required to be submitted pursuant to the June 30, 2003 recent revisions to 37 CFR § 1.98(a)(2)(i).

EXCEPT THAT:

- ☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- ☐ In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application:
- ☐ Copies of references [list as appropriate] listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. _____, filed _____.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

- ☐ The relevance of those listed references which are not in the English language is as follows:
- ☒ There are no listed references which are not in the English language.


Date: May 6, 2004

John A. Harrelson, Jr.

John A. Harrelson, Jr.

Registration No. 42,637

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office 	Docket No. TRTC-0003	Application No. 10/813,315
	Applicant Ramesh Babu Jayaraman, et al.	
	Filing Date March 30, 2004	Group Not Yet Assigned
	Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
1	Allen, R.D.M., et al., "Australian multicentre evaluation of a new polyurethane vascular access graft," <i>Aust. N.Z. J. Surg.</i> , 1996 , 66, 738-742	
2	Andrés, et al., "Antiproliferative strategies for the treatment of vascular proliferative disease," <i>Rodent Models for HIV-1 Infection and Disease</i> [retrieved on April 29, 2004], retrieved from the internet: http://www.bentham.org/cvpl-1/vicente-castro/vicente.htm , 1-21	
3	Chen, et al., "Recombinant mitotoxin basic fibroblast growth factor-saporin reduces venous anastomotic intimal hyperplasia in the arteriovenous graft," <i>Circulation</i> , 1996 , 94, 1989-1995	
4	Chen, C., et al., "Boundary layer infusion of heparin prevents thrombosis and reduces neointimal hyperplasia in venous polytetrafluoroethylene grafts without systemic anticoagulation," <i>J. Vasc. Surg.</i> , 1995 , 22, 237-247	
5	Clowes, A., "Prevention of neointimal hyperplasia – taxol, rapamycin, and radiation," <i>VascularWeb</i> , [retrieved on April 29, 2004], retrieved from the internet: http://www.vascularweb.org , 2 pages	
6	Clowes, A., "Session III – Management of intimal hyperplasia with gene therapy: The human response to arterial injury," <i>Lifeline Abstracts</i> , 2002 , [retrieved on April 29, 2004], retrieved from the internet: http://www.lifeline.prrri.com/abstracts/2002/abstract17.html , 4 pages	
7	Farrar, D.J., "Development of a prosthetic coronary artery bypass graft," <i>The Heart Surgery Forum</i> #2000-3141, 2000 , 3(1), 36-40	
8	ISC, "Implant sciences awarded grant to develop rapamycin-eluting stent graft," <i>Press Release</i> , 2002 , [retrieved on April 29, 2004], retrieved from the internet: http://www.implantsciences.com/cn/pr/2002/pr_02feb28.html , 2 pages	
9	Kelly, B.S., et al., "External beam radiation attenuates venous neointimal hyperplasia in a pig model of arteriovenous polytetrafluoroethylene (PTFE) graft stenosis," <i>Int. J. Radiation Oncology Biol. Phys.</i> , 2002 , 54(1), 263-269	
10	Neorx receives milestone payment under paclitaxel license for drug-eluting stent," <i>News Release</i> , 2002 , [retrieved on April 29, 2004], retrieved from internet: http://www.neorx.com/news_release_nov_22_2002.htm , 2 pages	
EXAMINER		DATE CONSIDERED

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. TRTC-0003	Application No. 10/813,315
		Applicant Ramesh Babu Jayaraman, et al.	
		Filing Date March 30, 2004	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	11	Presbitero, P., et al., "Drug-eluting stents do they make the difference?," <i>Minerva Cardioangiol</i> , 2002, 50(5), 431-442 [retrieved on April 29, 2004], retrieved on the internet (PubMed): http://www.ncbi.nlm.nih.gov , 2 pages	
	12	Scott, N.A., "Local delivery of an antithrombin inhibits platelet-dependent thrombosis," <i>Circulation</i> , 1994, 90, 1951-1955	
	13	The Drug Eluting Company, "Magic box – the stent coating machine," [retrieved on May 5, 2004], retrieved on the internet: http://www.translumina.de/magic_box_faq_en.html , 2 pages	
	14	The Drug Eluting Company, "Active coating," [retrieved on April 29, 2004], retrieved on the internet: http://www.translumina.de/coating_active_en.html , 1 page	
	15	The Drug Eluting Company, "YUKON DES is a premounted stent system with new surface finishing technology PEARL surface for individual coating application," [retrieved May 5, 2004], retrieved on the internet: http://www.translumina.de/yukon_des_en.html , 1 pages	
	16	The Drug Eluting Company, "Yukon DES technical details," [retrieved on August 28, 2003], retrieved on the internet: http://www.translumina.de/yukon_des_tech_en.html , 1 page	
	17	Thoratec Corp., "Patients & families: Vectra VAG," [retrieved on April 29, 2004] retrieved on the internet: http://www.thoratec.com/thoratec-patients/vectra_vag.htm , 5 pages	
	18	Veith, F., et al. (Eds.), "The Experts' techniques," <i>Vascular Web</i> , [retrieved on August 28, 2003], retrieved on the internet: http://www.vascularweb.org/resources/expertech.cfm , 2 pages	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office				Docket No. TRTC-0003		Application No. 10/813,315	
				Applicant Ramesh Babu Jayaraman, et al.			
				Filing Date March 30, 2004		Group Not Yet Assigned	
				Confirmation No. Not Yet Assigned			
U. S. PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Name	Class	Subclass	
	19	4,459,252	07/10/84	MacGregor	264	46.9	
	20	4,604,762	08/12/86	Robinson	623	1.44	
	21	4,675,361	06/23/87	Ward, Jr.	525	92	
	22	4,731,073	03/15/88	Robinson	623	1.44	
	23	4,861,830	08/29/89	Ward, Jr.	525	92	
	24	5,723,004	03/03/98	Dereume, et al.	623	1	
	25	6,273,913 B1	08/14/01	Wright, et al.	623	1.42	
	26	6,387,116 B1	05/14/02	McKenzie, et al.	623	1.1	
	27	6,429,232 B1	08/06/02	Kinsella, et al.	514	824	
	28	6,440,166 B1	08/27/02	Kolluri	623	1.4	
	29	6,585,995 B1	07/01/03	Hanson	424	424	
	30	6,589,546 B2	07/08/03	Kamath, et al.	424	423	
	31	6,592,885 B2	07/15/03	Phaneuf, et al.	424	404	
	32	6,599,928 B2	07/29/03	Kunz, et al.	514	411	
	33	2002/0107330 A1	08/08/02	Pinchuk, et al.	525	242	
	34	2002/0187288 A1	12/12/02	Lim, et al.	428	35.2	
EXAMINER				DATE CONSIDERED			